We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Novavax (NVAX - Free Report) was down 4.18% at $8.95. This change lagged the S&P 500's daily loss of 1.74%. Elsewhere, the Dow saw a downswing of 1.01%, while the tech-heavy Nasdaq depreciated by 2.38%.
The vaccine maker's stock has dropped by 1.99% in the past month, exceeding the Medical sector's loss of 7.17% and the S&P 500's loss of 4.99%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.31, signifying a 110.58% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $60.39 million, showing a 90.94% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.03 per share and revenue of $382.13 million, which would represent changes of -101.16% and -65.99%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 85.43% higher. Right now, Novavax possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 147, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest close session, Novavax (NVAX - Free Report) was down 4.18% at $8.95. This change lagged the S&P 500's daily loss of 1.74%. Elsewhere, the Dow saw a downswing of 1.01%, while the tech-heavy Nasdaq depreciated by 2.38%.
The vaccine maker's stock has dropped by 1.99% in the past month, exceeding the Medical sector's loss of 7.17% and the S&P 500's loss of 4.99%.
The investment community will be closely monitoring the performance of Novavax in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.31, signifying a 110.58% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $60.39 million, showing a 90.94% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.03 per share and revenue of $382.13 million, which would represent changes of -101.16% and -65.99%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 85.43% higher. Right now, Novavax possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 147, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.